Exhibit 99.1
BioDelivery Sciences Provides Corporate Update and
Reports Second Quarter 2016 Financial Results
BDSI targeting BUNAVAIL® profitability by end of 2017 following commercial restructuring, managed care wins
and improved operating margins
Two significant managed care agreements secured providing preferred access to BUNAVAIL
BUNAVAIL net revenue per prescription increased for the second consecutive quarter
BUNAVAIL cost of goods declined 16% versus first quarter 2016
BUNAVAIL gross profit increased by nearly 200% versus first quarter 2016
BELBUCA™ weekly prescriptions continue to grow reaching a high to date of >1,300
Top-line Phase 2b data for Clonidine Topical Gel study expected by end of year
Licensing agreement signed with Collegium Pharmaceutical for exclusive rights to develop and commercialize ONSOLIS® in U.S.
Strong Cash Position of $57.5 million at June 30, 2016; cash runway to third quarter 2017
RALEIGH, N.C., August 9, 2016-BioDelivery Sciences International, Inc. (NASDAQ: BDSI) today reported financial results for the second quarter ended June 30, 2016, and provided an update on recent business highlights and upcoming milestones.
BDSI’s total net revenue for the three-months ended June 30, 2016, was $5.0 million, an increase of 65% over the first quarter of 2016 and an increase of 189% over last year’s corresponding quarter. BUNAVAIL (buprenorphine and naloxone) buccal film (CIII) net revenue for the three months-ended June 30, 2016 was $2.1 million.
BUNAVAIL prescription sales remained stable in the second quarter from the prior quarter despite BDSI’s previously announced sales force consolidation and restructuring in May, while overall unit (film) sales increased 2%.
Net revenue per BUNAVAIL prescription increased in the second quarter over the first quarter of 2016, which is expected to continue through 2017. Cost of goods (COGS) decreased 16% due to the transition to a high-speed packaging line in May and are expected to improve an additional 30% by the end of 2017. As a result of the aforementioned improvements, the gross profit for BUNAVAIL improved by nearly 200% in the second quarter versus the first quarter.
Operating expenses decreased by $1.9 million from $18.4 million in the first quarter to $16.5 million in the second quarter. BUNAVAIL commercial costs remained comparable between quarters due to one-time expenses related to the consolidation and transition of the sales force from Quintiles to BDSI in May. However, savings of approximately $3 million per quarter are expected to be realized beginning with the third quarter of this year.
| | | | |
| |  | | |
Managed care contracts remain central to the future growth of BUNAVAIL, and two important new agreements were finalized recently. As announced in July, BDSI secured access to a commercial plan that will allow BUNAVAIL to move from its current non-formulary position to a preferred formulary position within this plan, while the current market leader is made non-preferred. The other branded buprenorphine/naloxone product will share preferred status with BUNAVAIL. This contract will go into effect on January 1, 2017, though the transition may begin sooner for some plans under the agreement. Additionally, and not previously announced, BUNAVAIL has been added to a second plan where it will replace Zubsolv and share preferred status with Suboxone film. BDSI did not previously have access within either plan.
Progress was made this past quarter in enacting important legislation increasing patient access to treatment for opioid dependence, which began with the final ruling by the Department of Health and Human Services (HHS) which increased the cap from 100 to 275 patients an individual physician can treat with buprenorphine. This ruling went into effect yesterday. HHS estimates that this could expand access to up to 90,000 additional patients in the first year following implementation which could translate into over half a million additional prescriptions. It is anticipated that participating doctors will begin having an impact on the prescription market starting in the fourth quarter of this year. Additionally, the President recently signed new legislation, referred to as the Comprehensive Addiction and Recovery Act, or CARA, which further expands access to care including allowing nurse practitioners and physician assistants to prescribe buprenorphine and provides funding for grants to expand access to medication assisted treatment.
“We are focused on bringing BUNAVAIL to profitability by the end of 2017 and made significant advances in that regard during the quarter,” said Dr. Mark A. Sirgo, President and Chief Executive Officer. “Our plan for bringing our commercial expenses more in line with our revenue began with the restructuring and consolidation of the sales force in May around high performing and future growth territories. This will result in the elimination of approximately $20 million in expenses through the end of 2017. We are actively seeking to drive BUNAVAIL prescription growth by improving our position on or securing additional managed care contracts as well as initiatives focused on driving more patients to BUNAVAIL in conjunction with the lifting of the patient cap and our direct to patient program. Simultaneously, we will continue efforts to improve our operating margins as we strive to achieve our goal of bringing BUNAVAIL to profitability by the end of 2017.”
Dr. Sirgo concluded, “Regarding the rest of our portfolio, we continue to be optimistic about the long-term success of BELBUCA based on both the considerable commercial and post-marketing effort that our partner Endo is putting behind the launch and initial favorable reports from healthcare providers and patients. BELBUCA also has favorable managed care receptivity and coverage. Further driving our optimism, BELBUCA hit a high to date of over 1300 prescriptions
| | | | |
| | | | |
last week. Separately, we continue to make significant progress with our product development pipeline. Our Phase 2b study of Clonidine Topical Gel for the treatment of painful diabetic neuropathy has reached its target enrollment, and we now anticipate top-line results ahead of schedule and before the end of this year, and our buprenorphine 30-day injection continues to progress toward IND submission and the start of our Phase 1 study. In addition, we successfully monetized ONSOLIS, which we expect to re-enter the market mid-2017, with our licensing agreement with Collegium Pharmaceutical. Finally, we remain in a strong financial position, as our cash runway extends into the third quarter of 2017. We are extremely optimistic on all business fronts as we move into the second half of the year.”
FINANCIAL HIGHLIGHTS
Second Quarter Ended June 30, 2016 Financial Results Overview
| | • | | Net revenue for the second quarter ended June 2016, was $5.0 million, comprised primarily of $2.1 million of BUNAVAIL revenue and $2.5 million of contract revenue related to the license agreement with Collegium, compared to $1.7 million in the second quarter of 2015. |
| | • | | Total operating expenses for the second quarter ended June 30, 2016, were $16.5 million, compared to $17.8 million in the second quarter of 2015. |
| | • | | Net loss for the second quarter ended June 30, 2016, was $16.5 million, or ($0.31) per diluted share, compared to a net loss of $19.2 million, or ($0.37) per diluted share, in the same period of 2015. |
Six Months Ended June 30, 2016 Financial Results Overview
| | • | | Total revenue for the six months ended June 30, 2016, was $8.0 million, compared to $14.8 million in the same period of 2015. |
| | • | | Total operating expenses for the six months ended June 30, 2016, were $34.9 million, compared to $37.5 million in the same period of 2015. |
| | • | | Net loss for the six months ended June 30, 2016, was $35.2 million, or ($0.66) per diluted share, compared to a net loss of $27.4 million, or ($0.53) per diluted share, in the same period of 2015. |
| | • | | BDSI had cash and cash equivalents of approximately $57.5 million at June 30, 2016. This compares to cash and cash equivalents of approximately $69.4 million at March 31, 2016. |
CORPORATE UPDATE AND RECENT ACCOMPLISHMENTS
BUNAVAIL (buprenorphine and naloxone) buccal film (CIII)
| | • | | BUNAVAIL prescription sales in the second quarter were relatively unchanged from the first quarter, while overall unit (film) sales increased 2%. Exclusive of Tennessee Medicaid, prescriptions for BUNAVAIL grew by 9% nationally, demonstrating continued underlying growth and adoption of BUNAVAIL. |
| | • | | Through the second quarter of 2016, nearly 3,300 physicians have prescribed BUNAVAIL since launch, with 364 new prescribers added during the second quarter. |
| | • | | Consolidation and transition from a contract sales organization to an internal sales force was completed during the second quarter. These changes are expected to reduce commercial expenses by approximately $20 million through the end of 2017. |
| | • | | Two important managed care contracts were secured providing preferred access to BUNAVAIL in plans where access to BUNAVAIL has been limited. |
| | • | | As announced in July, access to BUNAVAIL will be improved substantially in an important managed care plan from its current non-formulary position to a preferred formulary position, while the current market leader is made non-preferred. The other branded buprenorphine/naloxone product will share preferred status with BUNAVAIL. The contract goes into effect on January 1, 2017. |
| | • | | Additionally, and not previously announced, BUNAVAIL has been added to an additional commercial plan. BUNAVAIL replaced Zubsolv and will share preferred status with Suboxone film. The contract went into effect on July 1, 2016. |
| | • | | BUNAVAIL is now in a much improved positon to access these additional prescriptions. |
| | • | | Data presented at the International Conference on Opioids demonstrating that in Tennessee, prescriptions of Suboxone decreased from a weekly consistent peak of more than 1,600 to less than 100 within one month of the switch, while BUNAVAIL prescriptions increased from a low of 19 to approximately 600. This approximate 63 percent reduction in overall prescriptions in the plan remained throughout the measurement period analyzed, which could result in a savings of approximately $14 million to the state budget. |
| | • | | Following the final ruling by the Department of Health and Human Services, effective August 8, 2016, the limit on the number of patients an individual physician can treat with buprenorphine for opioid dependence has increased from 100 to 275. |
BELBUCA (buprenorphine) buccal film (CIII)
| | • | | BELBUCA prescriptions continue to grow, totaling more than 1,300 during the week ending July 29. The number of repeat prescriptions also continues to grow. |
| | • | | Endo reports increasing investments in new promotional efforts for BELBUCA. |
| | • | | Endo filed BELBUCA regulatory submission in Canada. |
ONSOLIS (fentanyl buccal soluble film) - Management of Breakthrough Pain in Opioid Tolerant Patients with Cancer
| | • | | Signed a licensing agreement under which BDSI granted the exclusive rights to develop and commercialize ONSOLIS in the U.S. to Collegium Pharmaceutical. Collegium is responsible for the future manufacturing, distribution, marketing and sales of ONSOLIS in the U.S. |
| | • | | BDSI received a $2.5 million upfront non-refundable payment, and will receive another $4 million upon the first commercial sale of ONSOLIS in the U.S., which is anticipated to take place by mid-2017. Meda shares in a significant portion of the proceeds from milestones and royalties from ONSOLIS. |
| | • | | BDSI is also eligible to receive up to $17 million in potential payments based on achievement of performance and sales milestones and upper-teen royalties based on various annual U.S. net sales thresholds. |
Clonidine Topical Gel – Painful Diabetic Neuropathy
| | • | | Multi-center, randomized, double-blind, placebo-controlled Phase 2b study of Clonidine Topical Gel has reached its randomization goal. |
| | • | | As a result, it is expected that topline study results will be available by the end of 2016, well ahead of schedule. |
Buprenorphine 30 Day Injection – Pain & Opioid Dependence
| | • | | Pre-clinical data demonstrates the ability of BDSI’s buprenorphine injection formulation to provide therapeutic plasma levels of buprenorphine out to one month. |
| | • | | Two pre-clinical studies are in process. Completion and analysis of these two studies will determine the timing of the Investigational New Drug (IND) submission. The submission timing is not anticipated to have an impact on the overall development timeline as activities to support the Phase 1 clinical study, are progressing. The study is expected to begin in the fourth quarter of this year. |
Key Anticipated 2016-2017 Milestones
| | • | | Last patient completes Clonidine Topical Gel Phase 2b study, with data expected by end of year. |
| | • | | IND filing of Buprenorphine 30 Day Injection for the treatment of opioid dependence and initiation of a single dose pharmacokinetic study are anticipated in the fourth quarter of 2016. |
| | • | | Implementation of recently awarded BUNAVAIL managed care contracts effective January 1, 2017. |
Conference Call & Webcast
Tuesday, August 9 @ 8:00 am Eastern Time
| | |
| Domestic: | | 888-427-9419 |
| International: | | 719-325-2361 |
| Passcode: | | 3069498 |
| Webcast: | | http://public.viavid.com/index.php?id=120421 |
Replays available through August 23rd:
| | |
| Domestic: | | 877-870-5176 |
| International: | | 858-384-5517 |
| Conference ID: | | 3069498 |
About BioDelivery Sciences International
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.
BDSI’s development strategy focuses on utilization of the FDA’s 505(b)(2) approval process. This regulatory pathway creates the potential for more timely and efficient approval of new formulations of previously approved therapeutics.
BDSI’s particular area of focus is the development and commercialization of products in the areas of pain management and addiction. These are areas where BDSI believes its drug delivery technologies and products can best be applied to address critical unmet medical needs. BDSI’s marketed products and those in development address serious and debilitating conditions such as opioid dependence, chronic pain, breakthrough cancer pain and painful diabetic neuropathy. BDSI’s headquarters is located in Raleigh, North Carolina.
For more information, please visit or follow us:
| | |
| Internet: | | www.bdsi.com |
| Facebook: | | Facebook.com/BioDeliverySI |
| Twitter: | | @BioDeliverySI |
BDSI markets BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) and ONSOLIS® (fentanyl buccal soluble film) (CII). BELBUCA™ (buprenorphine) buccal film (CIII) is commercialized in the U.S. by Endo Pharmaceuticals pursuant to the worldwide licensing and development agreement between BDSI and Endo. For full prescribing information and important safety information on BDSI products, including BOXED WARNINGS for ONSOLIS, please visitwww.bdsi.com where the Company promptly posts press releases, SEC filings and other important information or contact the Company at (800) 469-0261. For full prescribing and safety information on BELBUCA, please visitwww.belbuca.com.
Cautionary Note on Forward-Looking Statements
This press release and any statements of employees, representatives and partners of BioDelivery Sciences International, Inc. (the “Company”) related thereto (including, without limitation, at the presentation described herein) contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of
| | | | |
| | | | |
1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results (including, without limitation, the results of commercialization efforts for the Company’s approved products and the clinical trials for, and regulatory review of, the Company’s products in development) may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
BDSI®, BEMA® and BUNAVAIL® are registered trademarks of BioDelivery Sciences International, Inc. The BioDelivery Sciences and BUNAVAIL logos are trademarks owned by BioDelivery Sciences International, Inc. All other trademarks and tradenames are owned by their respective owners.
© 2016 BioDelivery Sciences International, Inc. All rights reserved.
Contacts
Investors:
Matthew P. Duffy
Managing Director
LifeSci Advisors, LLC
212-915-0685
matthew@lifesciadvisors.com
Al Medwar
Senior Vice President, Corporate and Business Development
BioDelivery Sciences International, Inc.
919-582-9050
amedwar@bdsi.com
Media:
Susan Forman/Laura Radocaj
Dian Griesel Int’l.
212-825-3210
sforman@dgicomm.com
lradocaj@dgicomm.com
��
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(U.S. DOLLARS, IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)
(Unaudited)
| | | | | | | | |
| | | June 30,
2016 | | | December 31,
2015 | |
| ASSETS | | | | | | | | |
Current assets: | | | | | | | | |
Cash and cash equivalents | | $ | 57,464 | | | $ | 83,560 | |
Accounts receivable, net | | | 2,408 | | | | 2,488 | |
Inventory | | | 4,426 | | | | 2,558 | |
Prepaid expenses and other current assets | | | 3,612 | | | | 3,933 | |
| | | | | | | | |
Total current assets | | | 67,910 | | | | 92,539 | |
Property and equipment, net | | | 4,299 | | | | 4,262 | |
Goodwill | | | 2,715 | | | | 2,715 | |
Other intangible assets, net | | | 2,771 | | | | 3,256 | |
| | | | | | | | |
Total assets | | $ | 77,695 | | | $ | 102,772 | |
| | | | | | | | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | | | | | | | | |
Current liabilities: | | | | | | | | |
Accounts payable and accrued liabilities | | $ | 19,059 | | | $ | 19,501 | |
Notes payable, current maturities, net | | | 7,533 | | | | 6,707 | |
Deferred revenue, current | | | 1,965 | | | | 1,875 | |
Derivative liability | | | 114 | | | | — | |
| | | | | | | | |
Total current liabilities | | | 28,671 | | | | 28,083 | |
Notes payable, less current maturities, net | | | 21,540 | | | | 22,168 | |
Deferred revenue, long-term | | | 20,000 | | | | 20,000 | |
Other long-term liabilities | | | 825 | | | | 825 | |
| | | | | | | | |
Total liabilities | | | 71,036 | | | | 71,076 | |
Commitments and contingencies (Notes 7 and 12) | | | — | | | | — | |
Stockholders’ equity: | | | | | | | | |
Preferred Stock, $.001 par value; 5,000,000 shares authorized; 2,093,155 shares of Series A Non-Voting Convertible Preferred Stock outstanding at June 30, 2016 and December 31, 2015 | | | 2 | | | | 2 | |
Common Stock, $.001 par value; 75,000,000 shares authorized; 53,610,470 and 52,730,799 shares issued; 53,594,979 and 52,715,308 shares outstanding at June 30, 2016 and December 31, 2015, respectively | | | 54 | | | | 53 | |
Additional paid-in capital | | | 285,072 | | | | 274,891 | |
Treasury stock, at cost, 15,491 shares | | | (47 | ) | | | (47 | ) |
Accumulated deficit | | | (278,422 | ) | | | (243,203 | ) |
| | | | | | | | |
Total stockholders’ equity | | | 6,659 | | | | 31,696 | |
| | | | | | | | |
Total liabilities and stockholders’ equity | | $ | 77,695 | | | $ | 102,772 | |
| | | | | | | | |
| | | | |
| | | | |
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. DOLLARS, IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)
(Unaudited)
| | | | | | | | | | | | | | | | |
| | | Three Months Ended June 30, | | | Six Months Ended June 30, | |
| | | 2016 | | | 2015 | | | 2016 | | | 2015 | |
Revenues: | | | | | | | | | | | | | | | | |
Product sales | | $ | 2,110 | | | $ | 833 | | | $ | 4,212 | | | $ | 1,510 | |
Product royalty revenues | | | 394 | | | | 469 | | | | 1,328 | | | | 663 | |
Research and development reimbursements | | | — | | | | 80 | | | | 4 | | | | 855 | |
Contract revenues | | | 2,500 | | | | 351 | | | | 2,500 | | | | 11,759 | |
| | | | | | | | | | | | | | | | |
Total Revenues: | | | 5,004 | | | | 1,733 | | | | 8,044 | | | | 14,787 | |
| | | | | | | | | | | | | | | | |
Cost of sales | | | 4,094 | | | | 2,621 | | | | 6,644 | | | | 3,745 | |
| | | | | | | | | | | | | | | | |
Expenses: | | | | | | | | | | | | | | | | |
Research and development | | | 4,008 | | | | 4,506 | | | | 9,385 | | | | 11,054 | |
Selling, general and administrative | | | 12,496 | | | | 13,287 | | | | 25,551 | | | | 26,468 | |
| | | | | | | | | | | | | | | | |
Total Expenses: | | | 16,504 | | | | 17,793 | | | | 34,936 | | | | 37,522 | |
| | | | | | | | | | | | | | | | |
Loss from operations | | | (15,594 | ) | | | (18,681 | ) | | | (33,536 | ) | | | (26,480 | ) |
Interest expense, net | | | (914 | ) | | | (527 | ) | | | (1,691 | ) | | | (947 | ) |
Derivative gain | | | 22 | | | | — | | | | 22 | | | | — | |
Other (expense) income, net | | | — | | | | (3 | ) | | | (14 | ) | | | 23 | |
| | | | | | | | | | | | | | | | |
Net loss | | $ | (16,486 | ) | | $ | (19,211 | ) | | $ | (35,219 | ) | | $ | (27,404 | ) |
| | | | | | | | | | | | | | | | |
Basic and diluted loss per share: | | $ | (0.31 | ) | | $ | (0.37 | ) | | $ | (0.66 | ) | | $ | (0.53 | ) |
| | | | | | | | | | | | | | | | |
Weighted average common stock shares outstanding: | | | 53,594,979 | | | | 52,401,747 | | | | 53,412,813 | | | | 52,156,657 | |
| | | | | | | | | | | | | | | | |
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(U.S. DOLLARS, IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)
(Unaudited)
| | | | | | | | |
| | | Six months ended June 30, | |
| | | 2016 | | | 2015 | |
Operating activities: | | | | | | | | |
Net loss | | $ | (35,219 | ) | | $ | (27,404 | ) |
Depreciation | | | 212 | | | | 167 | |
Accretion of debt discount | | | 198 | | | | 278 | |
Amortization of intangible assets | | | 485 | | | | 485 | |
Derivative liability | | | 114 | | | | — | |
Stock-based compensation expense | | | 7,457 | | | | 7,658 | |
Changes in assets and liabilities: | | | | | | | | |
Accounts receivable | | | 80 | | | | 1,614 | |
Inventories | | | (1,868 | ) | | | 295 | |
Prepaid expenses and other assets | | | 321 | | | | 133 | |
Accounts payable and accrued expenses | | | (441 | ) | | | (2,210 | ) |
Deferred revenue | | | 90 | | | | (366 | ) |
| | | | | | | | |
Net cash flows from operating activities | | | (28,571 | ) | | | (19,350 | ) |
| | | | | | | | |
Investing activities: | | | | | | | | |
Purchase of equipment | | | (249 | ) | | | (583 | ) |
| | | | | | | | |
Net cash flows from investing activities | | | (249 | ) | | | (583 | ) |
| | | | | | | | |
Financing activities: | | | | | | | | |
Proceeds from issuance of common stock | | | 2,459 | | | | — | |
Equity financing costs | | | 40 | | | | (40 | ) |
Proceeds from exercise of stock options | | | 225 | | | | 303 | |
Proceeds from exercise of common stock warrants | | | — | | | | 1 | |
Payment on note payable | | | — | | | | (3,335 | ) |
Proceeds from notes payable | | | — | | | | 20,667 | |
Payment of deferred financing fees | | | — | | | | (486 | ) |
Return of short swing profits | | | — | | | | 6 | |
| | | | | | | | |
Net cash flows from financing activities | | | 2,724 | | | | 17,116 | |
| | | | | | | | |
Net change in cash and cash equivalents | | | (26,096 | ) | | | (2,817 | ) |
Cash and cash equivalents at beginning of year | | | 83,560 | | | | 70,472 | |
| | | | | | | | |
Cash and cash equivalents at end of year | | $ | 57,464 | | | $ | 67,655 | |
| | | | | | | | |
Cash paid for interest | | $ | 1,358 | | | $ | 491 | |
